Mixed results for additional immunotherapy to standard care in stage III NSCLC
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
Studies shed new light on the role of the gut microbiome in immunotherapy toxicity
Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration
Immunotherapy added to radiotherapy does not improve outcomes in early-stage NSCLC
A lack of benefit coupled with increased toxicity was reported in patients with stage I/II inoperable disease in the KEYNOTE-867 trial
Three new Pan-Asian-adapted guidelines at ESMO Asia Congress
The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer
A c-Met directed antibody-drug conjugate shows preliminary activity in a NSCLC cohort
Efficacy and safety of telisotuzumab adizutecan was investigated in patients with EGFR wild type non-squamous disease
Alectinib shows benefit across genetic profiles in resected ALK-positive NSCLC
New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population
Liquid biopsy plays a growing role in early-stage lung cancer
Research is moving forward to understand the value of this blood-based technology as a prognostic tool
Study findings confirm the benefits of BRAF and MEK inhibitors in mutated non-small cell lung cancer
Longer duration of efficacy reported for encorafenib plus binimetinib as a treatment for NSCLC harbouring a BRAF V600 mutation
Novel ALK-selective TKIs show early efficacy in advanced NSCLC with rare mutations
Further studies are needed to understand the position of the fourth-generation agents NVL-520 and NVL-655 in the treatment paradigm of mutated lung cancer
New data add to current knowledge on how to optimise treatment in EGFR-mutant NSCLC
The use of targeted agents in first and subsequent lines of therapy is improving outcomes in patients with mutated lung cancer progressing on standard chemotherapy, but a biomarker- or precision-guided approach is needed